- Home
- GLTO vs ELWS Comparison
GLTO vs ELWS Comparison
Compare GLTO & ELWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- ELWS
- Stock Information
- Founded
- GLTO 2011
- ELWS 2018
- Country
- GLTO Denmark
- ELWS Japan
- Employees
- GLTO N/A
- ELWS N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- ELWS
- Sector
- GLTO Health Care
- ELWS
- Exchange
- GLTO Nasdaq
- ELWS Nasdaq
- Market Cap
- GLTO 6.5M
- ELWS 6.2M
- IPO Year
- GLTO 2020
- ELWS 2023
- Fundamental
- Price
- GLTO $5.50
- ELWS $3.09
- Analyst Decision
- GLTO Buy
- ELWS
- Analyst Count
- GLTO 1
- ELWS 0
- Target Price
- GLTO $10.00
- ELWS N/A
- AVG Volume (30 Days)
- GLTO 21.2K
- ELWS 20.0K
- Earning Date
- GLTO 03-07-2025
- ELWS 12-31-2024
- Dividend Yield
- GLTO N/A
- ELWS N/A
- EPS Growth
- GLTO N/A
- ELWS N/A
- EPS
- GLTO N/A
- ELWS N/A
- Revenue
- GLTO N/A
- ELWS $1,139,113.00
- Revenue This Year
- GLTO N/A
- ELWS N/A
- Revenue Next Year
- GLTO N/A
- ELWS N/A
- P/E Ratio
- GLTO N/A
- ELWS N/A
- Revenue Growth
- GLTO N/A
- ELWS 285.14
- 52 Week Low
- GLTO $4.40
- ELWS $1.04
- 52 Week High
- GLTO $23.50
- ELWS $13.00
- Technical
- Relative Strength Index (RSI)
- GLTO 52.98
- ELWS 55.42
- Support Level
- GLTO $4.60
- ELWS $2.75
- Resistance Level
- GLTO $5.98
- ELWS $2.99
- Average True Range (ATR)
- GLTO 0.42
- ELWS 0.22
- MACD
- GLTO 0.08
- ELWS 0.01
- Stochastic Oscillator
- GLTO 65.22
- ELWS 74.58
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.